Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Other financing activities (2018 - 2025)

Collegium Pharmaceutical has reported Other financing activities over the past 3 years, most recently at $964000.0 for Q3 2025.

  • Quarterly results put Other financing activities at $964000.0 for Q3 2025, up 578.87% from a year ago — trailing twelve months through Sep 2025 was $12.1 million (down 35.81% YoY), and the annual figure for FY2015 was -$16000.0, changed.
  • Other financing activities for Q3 2025 was $964000.0 at Collegium Pharmaceutical, up from $428000.0 in the prior quarter.
  • Over the last five years, Other financing activities for COLL hit a ceiling of $12.9 million in Q1 2024 and a floor of $142000.0 in Q3 2024.